Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Botulinum toxin in the management of chronic migraine: clinical evidence and experience.

Literature DB >> 28382110

Botulinum toxin in the management of chronic migraine: clinical evidence and experience.

Claus M Escher¹, Lejla Paracka², Dirk Dressler², Katja Kollewe³.

Abstract

Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010. It has been shown that onabotulinumtoxinA is effective in the reduction of headache frequency and severity in patients with CM. Treatment is well tolerated by the patients. This review reports on the history of botulinum neurotoxin (BoNT) in CM and presents the current clinical evidence for the use of onabotulinumtoxinA in the treatment of CM.

Entities: Disease Species

Keywords: Botox®; botulinum neurotoxin; chronic daily headache; chronic migraine; onabotulinumtoxinA

Year: 2016 PMID： 28382110 PMCID： PMC5367647 DOI： 10.1177/1756285616677005

Source DB: PubMed Journal: Ther Adv Neurol Disord ISSN： 1756-2856 Impact factor: 6.570

71 in total

1. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors: S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal: Cephalalgia Date: 2010-03-17 Impact factor: 6.292

2. The Use of Botulinum Toxin in the Management of Headache Disorders.

Authors: Stephen D Silberstein
Journal: Semin Neurol Date: 2016-02-11 Impact factor: 3.420

3. Facing depression with botulinum toxin: a randomized controlled trial.

Authors: M Axel Wollmer; Claas de Boer; Nadeem Kalak; Johannes Beck; Thomas Götz; Tina Schmidt; Muris Hodzic; Ursula Bayer; Thilo Kollmann; Katja Kollewe; Daniela Sönmez; Katja Duntsch; Martin D Haug; Manfred Schedlowski; Martin Hatzinger; Dirk Dressler; Serge Brand; Edith Holsboer-Trachsler; Tillmann H C Kruger
Journal: J Psychiatr Res Date: 2012-02-24 Impact factor: 4.791

4. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

Authors: Ninan T Mathew; Benjamin M Frishberg; Marek Gawel; Rozalina Dimitrova; John Gibson; Catherine Turkel
Journal: Headache Date: 2005-04 Impact factor: 5.887

5. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.

Authors: W J Binder; M F Brin; A Blitzer; L D Schoenrock; J M Pogoda
Journal: Otolaryngol Head Neck Surg Date: 2000-12 Impact factor: 3.497

6. Topiramate in the treatment of chronic migraine.

Authors: M Silvestrini; M Bartolini; M Coccia; R Baruffaldi; R Taffi; L Provinciali
Journal: Cephalalgia Date: 2003-10 Impact factor: 6.292

Review 7. Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options.

Authors: Hans-Christoph Diener; Kasja Solbach; Dagny Holle; Charly Gaul
Journal: Clin Med (Lond) Date: 2015-08 Impact factor: 2.659

8. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial.

Authors: Eric Finzi; Norman E Rosenthal
Journal: J Psychiatr Res Date: 2013-12-01 Impact factor: 4.791

9. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors: H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal: Cephalalgia Date: 2007-04-18 Impact factor: 6.292

10. Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.

Authors: Modar Khalil; Hassan W Zafar; Victoria Quarshie; Fayyaz Ahmed
Journal: J Headache Pain Date: 2014-09-01 Impact factor: 7.277

15 in total

Review 1. Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action.

Authors: Till Sprenger; M Viana; C Tassorelli
Journal: Neurotherapeutics Date: 2018-04 Impact factor: 7.620

Review 2. Methodological approaches to botulinum toxin for the treatment of chronic pelvic pain, vaginismus, and vulvar pain disorders.

Authors: Barbara Illowsky Karp; Hannah Tandon; Deionna Vigil; Pamela Stratton
Journal: Int Urogynecol J Date: 2019-01-07 Impact factor: 2.894

3. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series.

Authors: Tahlia Toni; Rayce Tamanaha; Bashak Newman; Yutong Liang; James Lee; Enrique Carrazana; Vimala Vajjala; Jason Viereck; Kore Kai Liow
Journal: Neurol Sci Date: 2021-08-18 Impact factor: 3.307

4. Three Dimensions of Association Link Migraine Symptoms and Functional Connectivity.

Authors: Samuel R Krimmel; Danielle D DeSouza; Michael L Keaser; Bharati M Sanjanwala; Robert P Cowan; Martin A Lindquist; Jennifer A Haythornthwaite; David A Seminowicz
Journal: J Neurosci Date: 2022-06-29 Impact factor: 6.709

5. OnabotulinumtoxinA in chronic migraine: is the response dose dependent?

Authors: Ali Zandieh; Fred Michael Cutrer
Journal: BMC Neurol Date: 2022-06-13 Impact factor: 2.903

6. Interactions between nociceptor sensory neurons and microbial pathogens in pain.

Authors: Larissa Staurengo-Ferrari; Liwen Deng; Isaac M Chiu
Journal: Pain Date: 2022-11-01 Impact factor: 7.926

7. Non-invasive Intrauterine Administration of Botulinum Toxin A Enhances Endometrial Angiogenesis and Improves the Rates of Embryo Implantation.

Authors: Hwa Seon Koo; Min-Ji Yoon; Seon-Hwa Hong; Jungho Ahn; Hwijae Cha; Danbi Lee; Chan Woo Park; Youn-Jung Kang
Journal: Reprod Sci Date: 2021-03-01 Impact factor: 3.060